Fig. 5.
Fig. 5. Expression of Bcl-2 by virus-specific CD8+ T cells before and after the resolution of AIM. / PBMC samples were isolated from 1 patient during (acute) and 1 year after the resolution of AIM (chronic). These samples were analyzed by 4-color flow cytometry for CD8, latent or lytic EBV specificity, CD45RA, and the anti-apoptotic molecule Bcl-2. The expression of Bcl-2 by CD45RA+ and CD45RA− T cells within the total CD8+, lytic, and latent epitope-specific cells is shown (A). The relative level of Bcl-2 expression (MFI) before and after resolution of AIM in the total CD8+ population of the same patient as above (squares), the CD45RA+tetramer-positive cells (circles), or CD45RA−tetramer-positive cells (triangles) were determined in cells specific for lytic (B) and latent (C) EBV epitopes. Results are representative of 5 separate experiments.

Expression of Bcl-2 by virus-specific CD8+ T cells before and after the resolution of AIM.

PBMC samples were isolated from 1 patient during (acute) and 1 year after the resolution of AIM (chronic). These samples were analyzed by 4-color flow cytometry for CD8, latent or lytic EBV specificity, CD45RA, and the anti-apoptotic molecule Bcl-2. The expression of Bcl-2 by CD45RA+ and CD45RA T cells within the total CD8+, lytic, and latent epitope-specific cells is shown (A). The relative level of Bcl-2 expression (MFI) before and after resolution of AIM in the total CD8+ population of the same patient as above (squares), the CD45RA+tetramer-positive cells (circles), or CD45RAtetramer-positive cells (triangles) were determined in cells specific for lytic (B) and latent (C) EBV epitopes. Results are representative of 5 separate experiments.

Close Modal

or Create an Account

Close Modal
Close Modal